Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1363Prostatic Neoplasms 1106Multiple Myeloma 872Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

vistusertib 1ribociclib 1Tamoxifen 1Letrozole 1Goserelin 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Advanced Metastatic Breast Cancer × Clear all
NCT01597388 2026-02-24

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

AstraZeneca

Phase 1 Completed
99 enrolled 61 charts
Breast

Advanced Metastatic Breast Cancer

NCT02278120 2024-03-12

MONALEESA-7

Novartis

Phase 3 Completed
672 enrolled 16 charts 1 FDA
Breast

Advanced Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡